Skeletal Radiology

, Volume 40, Issue 3, pp 295–302

Recognition of fibrous dysplasia of bone mimicking skeletal metastasis on 18F-FDG PET/CT imaging

  • Ming Gang Su
  • Rong Tian
  • Qiu Ping Fan
  • Ye Tian
  • Fang Lan Li
  • Lin Li
  • An Ren Kuang
  • John Howard Miller
Scientific Article



Fibrous dysplasia of bone (FDB) reveals intense 18F-FDG uptake mimicking metastases on 18F-FDG PET/CT. We reviewed sites of FDB revealed by 18F-FDG PET/CT imaging to allow identification of this abnormality.

Materials and Methods

Eleven patients (7 male, 4 female, aged 16–78 years) were evaluated after 55 MBq (0.15 mCi)/kg 18F-FDG utilizing a 16-slice multiple detector CT (MDCT) whole-body PET scanner, with LOR algorithm 3D reconstruction. One- and 2-h imaging was performed in 9 patients. Standard uptake value (SUV) for each lesion, on early and delayed imaging, was calculated. Lesions were confirmed in 6 patients by biopsy. The PET images correlated with MDCT to establish the imaging characteristics.


Solitary lesions were found in 4 patients, two lesions in 1 patient, and in 6 patients there were multiple bone lesions. The SUVearly ranged from 1.23 to 9.64 with an average of 3.76 ± 2.40. The SUVdelayed ranged from 1.76 to 11.42 with an average of 4.51 ± 3.07. The SUVdelayed decreased or increased slightly (−31% to 5%) in 6 of our patients, and increased significantly (11% to 39%) in 3. There was a negative correlation between SUVs and age, as well as the number of affected bones.


In our study, FDB had wide skeletal distribution with variability of 18F-FDG uptake and CT appearance. SUV in the delayed stage was seen to either decrease or increase on dual-time 18F-FDG PET scanning. It is very important to recognize the characteristics of this skeletal dysplasia to allow differentiation from skeletal metastasis.


18F-FDG PET/CT Children and adults Skeletal dysplasia Fibrous dysplasia 


  1. 1.
    Campanacci M. Bone and soft tissue tumors: clinical features, imaging, pathology and treatment. 2nd ed. New York: Springer; 1999.Google Scholar
  2. 2.
    Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the Mc-Cune-Albright Syndrome. N EngI J Med. 1991;325:1688–95.CrossRefGoogle Scholar
  3. 3.
    DiCaprio MR, Enneking WF. Fibrous dysplasia. pathophysiology, evaluation, and treatment. J Bone Joint Surg Am. 2005;87:1848–64.CrossRefPubMedGoogle Scholar
  4. 4.
    Parekh SG, Donthineni-Rao R, Ricchetti E, Lackman RD. Fibrous dysplasia. J Am Acad Orthop Surg. 2004;12:305–13.PubMedGoogle Scholar
  5. 5.
    Fitzpatrick KA, Taljanovic MS, Speer DP, Graham AR, Jacobson JA, Barnes GR, et al. Imaging findings of fibrous dysplasia with histopathologic and intraoperative correlation. AJR Am J Roentgenol. 2004;182:1389–98.PubMedGoogle Scholar
  6. 6.
    Zhuang HM, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li P, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42:1412–7.PubMedGoogle Scholar
  7. 7.
    Demura Y, Tsuchida T, Ishizaki T, Mizuno S, Totani Y, Ameshima S, et al. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med. 2003;44:540–8.PubMedGoogle Scholar
  8. 8.
    Aoki J, Watanabe H, Shinozaki T, Takagishi K, Ishijima H, Oya N, et al. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology. 2001;219:774–7.PubMedGoogle Scholar
  9. 9.
    Schulte M, Brecht-Krauss D, Heymer B, Guhlmann A, Hartwig E, Sarkar MR, et al. Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET. J Nucl Med. 2000;41:1695–701.PubMedGoogle Scholar
  10. 10.
    Von Falck C, Rosenthal H, Laenger F, Lotz J, Knapp WH, Galanski M. Avid uptake of [18F]-FDG in fibrous dysplasia can mimic skeletal involvement in Hodgkin’s disease. Eur J Nucl Med Mol Imaging. 2008;35:223.CrossRefGoogle Scholar
  11. 11.
    Stegger L, Juergens KU, Kliesch S, Wormanns D, Weckesser M. Unexpected finding of elevated glucose uptake in fibrous dysplasia mimicking malignancy: contradicting metabolism and morphology in combined PET/CT. Eur Radiol. 2007;17:1784–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Zou KH, Tuncali K, Silverman SG. Correlation and simple linear regression. Radiology. 2003;227:617–28.CrossRefPubMedGoogle Scholar
  13. 13.
    Hellwig D, Graeter TP, Ukena D, Groeschel A, Sybrecht GW, Schaefers H, et al. 18F-FDG PET for mediastinal staging of lung cancer: which SUV threshold makes sense? J Nucl Med. 2007;48:1761–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Matthies A, Hickeson M, Cuchiara A, Alavi A. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med. 2002;43:871–5.PubMedGoogle Scholar
  15. 15.
    Hart ES, Kelly MH, Brillante B, Chen CC, Ziran N, Lee JS, et al. Onset, progression, and plateau of skeletal lesions in fibrous dysplasia and the relationship to functional outcome. J Bone Miner Res. 2007;22:1468–74.CrossRefPubMedGoogle Scholar
  16. 16.
    Terpstra L, Rauch F, Plotkin H, Travers R, Glorieux FH. Bone mineralization in polyostotic fibrous dysplasia: histomorphometric analysis. J Bone Miner Res. 2002;17:1949–53.CrossRefPubMedGoogle Scholar
  17. 17.
    Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972–80.PubMedGoogle Scholar
  18. 18.
    Goodin GS, Shulkin BL, Kaufman RA, McCarville MB. PET/CT characterization of fibroosseous defects in children: 18F-FDG uptake can mimic metastatic disease. AJR Am J Roentgenol. 2006;187:1124–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Toba M, Hayashida K, Imakita S, Fukuchi K, Kume N, Shimotsu Y, et al. Increased bone mineral turnover without increased glucose utilization in sclerotic and hyperplastic change in fibrous dysplasia. Ann Nucl Med. 1998;12:153–5.CrossRefPubMedGoogle Scholar
  20. 20.
    Sahlmann CO, Siefker U, Meller J. Dual time point 2-[18F]fluoro-20-deoxyglucose positron emission tomography in chronic bacterial osteomyelitis. Nucl Med Commun. 2004;25:819–23.CrossRefPubMedGoogle Scholar
  21. 21.
    Israel O, Goldberg A, Nachtigal A, Militianu D, Bar-Shalom R, Keidar Z, et al. FDG-PET and CT patterns of bone metastases and their relationship to previously administered anti-cancer therapy. Eur J Nucl Med Mol Imaging. 2006;33:1280–4.CrossRefPubMedGoogle Scholar
  22. 22.
    Nakai T, Okuyamal C, Kubota T, Yamada K, Ushijima Y, Taniike K, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging. 2005;32:1253–8.CrossRefPubMedGoogle Scholar

Copyright information

© ISS 2010

Authors and Affiliations

  • Ming Gang Su
    • 1
  • Rong Tian
    • 1
  • Qiu Ping Fan
    • 1
  • Ye Tian
    • 1
  • Fang Lan Li
    • 1
  • Lin Li
    • 1
  • An Ren Kuang
    • 1
  • John Howard Miller
    • 2
  1. 1.National Key Discipline of Medical Imaging and Nuclear Medicine, Department of Nuclear Medicine, West China HospitalSichuan University School of MedicineChengduPeople’s Republic of China
  2. 2.Division of Pediatric Radiology, Department of RadiologyLoma Linda University School of MedicineLoma LindaUSA

Personalised recommendations